Back to Online Symposia Home Page
|
|
About this Activity
This segment will provide clinicians with an increased awareness of the Pathophysiological mechanisms involved in Acute Coronary Syndrome and help them to understand the treatment paradigms for ACS. Recent practice guidelines will be outlined and emerging therapies in the management of ACS for the prevention of restenosis and stent thrombosis will be compared and contrasted. The importance of early intervention and treatment will also be discussed.
Learning Objectives
By participating in this activity, the learner will be able to:
- Identify the pathophysiological mechanisms involved in ACS
- Evaluate the treatment paradigms for ACS and outline recent practice guidelines; and
- Compare and contrast emerging therapies in the management of primary care
Who Will Benefit
This activity was designed to meet the continuing education needs of Primary Care Physicians and other Healthcare Professionals.
Your Distinguished Faculty
 Michael S. Lee, MD is an interventional cardiologist, Assistant Clinical Professor of Medicine, and the Associate Director of Interventional Cardiology Research at the UCLA School of Medicine.
Faculty
Disclosures
Dr. Lee is a member of the Speakers Bureau for Boston Scientific, Takeda, BMS, AstraZeneca and Schering-Plough.
|
Commercial
Support
This program is supported by an educational grant from Daiichi-Sankyo, Inc. and Eli Lilly and Company.
Disclaimers
The content of this podcast may include product information that is inconsistent with or outside the approved labeling for these products in the United States. Before prescribing any medication, you must familiarize yourself with the manufacturer’s product information.
To earn continuing
education credit, view this online course and complete the posttest and
evaluation provided. A passing score of 75% or more
must be achieved on the posttest. A link is provided within this online
activity to access the posttest and evaluation. You will have the option of
printing a CME Certificate for your records after submission of the
evaluation.
CME LLC and Daiichi-Sankyo, Inc. and Eli Lilly and Company are not responsible for the faculty’s statements, materials, acts or omissions.
|
|
Continuing
Medical Education
CME LLC is accredited by the Accreditation Council for Continuing Medical
Education to provide continuing medical education for physicians.
CME LLC designates this
educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate
with the extent of their participation in the activity.
Online Date: 12/20/08
Credit Expiration Date: 12/20/09
This activity is based on the symposium Expanding the Armamentarium in the Treatment of Insomnia: Understanding the Pharmacology of Current and Emerging Treatments on October 30, 2008 in San Diego, CA and may not reflect the most current data. Participants who
attended the live symposium mentioned above cannot claim credit for this
activity.
|